CP1 Share Price History
21 Jul, 2020
The Company is now in discussions with animal health partners to advance the commercialisation of DermaCann® in various regulatory and non-regulatory markets. SYDNEY, July 21, 2020 /CNW/ --Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") has released results from its safety and efficacy study for DermaCann®, an oral nutraceutical developed for healthy skin and immune function for dogs.
12 May, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
12 Feb, 2020
It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...
08 Jan, 2020
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") is pleased to announce that following an 18 month evaluation, it has been granted exclusive global rights to commercialise patented MicroMAX® microencapsulation technology by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) for use in the field of Animal Therapeutics.
06 Nov, 2019
CannPal Animal Therapeutics Limited's (ASX:CP1): CannPal Animal Therapeutics Limited engages in the research and...
23 Sep, 2019
The big shareholder groups in CannPal Animal Therapeutics Limited (ASX:CP1) have power over the company. Institutions...
09 Aug, 2019
CannPal Animal Therapeutics Limited (ASX:CP1) is a company with exceptional fundamental characteristics. Upon building...